Trivalent inactivated subunit influenza vaccine Influvac®: 30-year experience of safety and immunogenicity

Conclusions This review of the 30-year clinical experience with Influvac® found that the overall benefit-to-risk ratio is positive for all age groups from 6months upwards. The currently available evidence from the many clinical trials that have been performed confirms that Influvac® remains an effective and safe vaccine for preventing seasonal influenza.
Source: Trials in Vaccinology - Category: Infectious Diseases Source Type: research